NASDAQ OMX

Immunicum AB (publ) Announces Enrollment of First United States Patient in the Ongoing Phase 2 MERECA Trial for Ilixadencel

Dela

 

Press Release

10 August 2017

Immunicum AB (publ) Announces Enrollment of First United States Patient in the Ongoing Phase 2 MERECA Trial for Ilixadencel

Immunicum AB (publ; First North Premier: IMMU.ST), a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced the enrollment  of the first patient in the United States (US) as part of the Company's ongoing global Phase 2 MERECA (MEtastatic REnal Cell CArcinoma) trial. The trial is investigating the safety and efficacy of Immunicum's lead drug candidate ilixadencel, formerly known as INTUVAX, a cancer immune primer that is designed to specifically reactivate the patient's immune system to recognize and destroy tumor cells.

"With the first metastatic kidney cancer patient enrolled in the United States, we have achieved another important milestone for Immunicum. The continued expansion of our clinical program underscores the dedication of our team to realize ilixadencel's potential and to execute a global clinical trial including meeting all regulatory and manufacturing requirements in the US which are significant for a cell-based therapy," said Dr. Peter Suenaert, CMO of Immunicum.

"This is a significant step for Immunicum and I am very pleased that the first patient has been  enrolled in the US and that we are continuing to advance ilixadencel, our innovative immune priming cell therapy approach, through the clinic," said Carlos de Sousa, CEO of Immunicum.

The MERECA study is currently ongoing in eight European countries and is now rolled out in the US.  It examines the safety, tumor-specific immune activation and potential for clinical efficacy of two intratumoral doses of ilixadencel before surgical removal of the tumor-affected kidney and subsequent systemic treatment with sunitinib. In addition to analyzing the immune system activating effects of ilixadencel treatment, the study will also provide data on the clinical benefit through survival rate at 18 months and median overall survival for all patients.

About renal cell cancer / carcinoma
There are approximately 273,000 new cases of Renal Cell Cancer (RCC) diagnosed worldwide each year, representing approximately two percent of all cancers. The therapeutic effect of existing treatments, called directed therapies, is often of short duration, with limited survival rate gain. With no alternatives to these therapies, there exists a relatively large unsatisfied medical need for new treatments that are effective, more cost-efficient and have less unwanted side effects.

About ilixadencel
Ilixadencel cell therapy product (formerly known as INTUVAX) is a cancer immune primer, developed for the treatment of solid tumors. Its active ingredient is activated allogeneic dendritic cells, derived from healthy blood donors. Intratumoral injection of these cells is expected to lead to an inflammatory response which in turn leads to tumor-specific activation of the patient's cytotoxic T-lymphocytes.

For more information, please contact:

Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com

Investor Relations Sweden

Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: helena.stangberg@halvarsson.se

Investor and Media Relations EU/US

MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Telephone: +49 89 2424 3494 or +49 175 5711562
E-mail: gschweitzer@macbiocom.com or smay@macbiocom.com

The Company's Certified Adviser is Redeye AB
Telephone: +46 (0) 8 545 013 31
www.redeye.se

About Immunicum AB (publ)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq First North Premier. www.immunicum.com

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Raven Indusries Releases CR12(TM) Field Computer18.6.2018 16:49Pressmeddelande

12-Inch Display With Field Planning Features Helps Farmers Save Time and Increase Efficiencies MIDDENMEER, The Netherlands, June 18, 2018 (GLOBE NEWSWIRE) -- Raven Industries (NASDAQ:RAVN) announced today the release of a new, larger field computer: the CR12(TM). Utilizing the same powerful functionality as the CR7(TM) field computer, the CR12 offers an extensive field planning feature for increased efficiencies. Built with a durable magnesium waterproof housing and a full glass capacitive touchscreen with high brightness, the CR12 also boasts a wider, 12.1-inch display. The CR12 joins the CR7 as the latest field computer in the CRX display family. This powerful operating system features easy job set-up, fewer touches and greater efficiencies - empowering the user with extraordinary data management capabilities. A simple widget concept, easily accessible settings, and ISO Universal Terminal and Task Controller capabilities make this mighty unit an affordable, plug-and-play system. Like

FPGA programming solution goes live at AEE 2018 in latest version of SLX18.6.2018 15:00Pressmeddelande

Silexica / FPGA programming solution goes live at AEE 2018 in latest version of SLX . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Industry-first solution fully explores the design space to optimize hardware/software partitioning SLX automatically inserts pragmas and rewrites code to make it High-Level Synthesis (HLS) ready Solution designed in collaboration with customers including Ricoh SAN JOSE, Calif. and COLOGNE, Germany, June 18, 2018 (GLOBE NEWSWIRE) -- Silexica will launch a new solution within SLX to support the increasing use of FPGAs for embedded computing tasks such as sensor fusion and deep learning. It has been developed in partnership with Ricoh and other customers who will use the solution for industrial automation and defense projects. The technology will be presented at Silexica's first appearance one of the world's biggest avionics exhibitions - AEE held in Munich from June 19-20. The

Immunicum AB (publ) meddelar publicering av en översiktsartikel kring ilixadencel-konceptet i Pharmaceutical Research18.6.2018 14:00Pressmeddelande

Pressmeddelande 18 juni 2018 Immunicum AB (publ) meddelar publicering av en översiktsartikel kring ilixadencel-konceptet i Pharmaceutical Research Immunicum AB (publ; IMMU.ST) offentliggjorde i dag online-publiceringen av en översiktsartikel av den senaste tidens utveckling inom immunonkologiforskning, med särskilt fokus på tidigare publicerade data som stöder värdet av bolagets ledande program, ilixadencel. Artikeln, med titeln "Ilixadencel - An Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration" publicerades on-line i Pharmaceutical Research , American Association of Pharmaceutical Scientists officiella tidskrift. Artikeln finns via följande länk https://link.springer.com/article/10.1007/s11095-018-2438-x - Det är en ära för vårt forsknings- och utvecklingsteam på Immunicum att bli erbjudna att skriva denna omfattande översikt som tar upp ilixadencels verkningsmekanism mot bakrund av de senaste upptäckterna gällande immunaktivering mot cancer. Våra preklin

Goldman Sachs and Cisco to Host Tech Talk on Data Center Networking18.6.2018 14:00Pressmeddelande

SAN JOSE, Calif., June 18, 2018 (GLOBE NEWSWIRE) -- Cisco will host a conference call with Goldman Sachs and Cisco's Ish Limkakeng, SVP, Product Management, Data Center Networking Group. The discussion will focus on Cisco's data center networking strategy, comprehensive portfolio, and its competitive advantage as customers seek highly secure and differentiated offerings. Interested parties can find more information on Cisco's Investor Relations website at https://investor.cisco.com. No new financial information will be discussed on this conference call. Date: Thursday, June 21, 2018 Time: 8:30 am PT / 11:30 am ET Speaker: Ish Limkakeng, SVP, Product Management, Data Center Networking Group Moderator: Goldman Sachs' Rod Hall, Managing Director Participant Dial in: Toll Free: 877-208-2954 International Number: 973-528-0056 Passcode: 201872 Replay Information (available until July 5, 2018): Toll Free: 800-332-6854 International Number: 973-528-0005 Passcode: 201872 This event will be webc

Immunicum AB (publ) Announces Publication of Scientific Review of Ilixadencel Approach in Pharmaceutical Research18.6.2018 14:00Pressmeddelande

Press Release 18 June 2018 Immunicum AB (publ) Announces Publication of Scientific Review of Ilixadencel Approach in Pharmaceutical Research Immunicum AB (publ; IMMU.ST) announced today the online publication of a review article providing an overview of recent developments in immuno-oncology research, specifically focusing on previously published data supporting the value of its lead program, ilixadencel. The article, titled "Ilixadencel - An Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration", was published in Pharmaceutical Research , the official journal of the American Association of Pharmaceutical Scientists. The article can be accessed via the following link https://link.springer.com/article/10.1007/s11095-018-2438-x "It is an honor for our research and development team at Immunicum to be invited to write this in-depth review article covering ilixadencel's mode of action in context of the most recent discoveries in anti-cancer immune activation," comme

DSM Sinochem Pharmaceuticals launches Atorvastatin film-coated tablets, expanding its finished dosage statins portfolio18.6.2018 11:23Pressmeddelande

Rijswijk, 18 June 2018, June 18, 2018 (GLOBE NEWSWIRE) -- Building upon its first generic finished dosage statin launch (Rosuvastatin) in January of this year, DSM Sinochem Pharmaceuticals (DSP) has this month released its fully backward-integrated, generic Atorvastatin drug product within the EU. Additional markets are scheduled to follow later in the year.Atorvastatin is used primarily in the prevention of cardiovascular disease and hyperlipidemia, commonly known as high cholesterol, the number one cause of death worldwide. Currently, statins are the most prescribed drug family globally in the fight against these potentially life-threatening conditions. Expanding statins portfolio With the launch now of Atorvastatin finished dosage formulation, coming on the heels of the successful launch of Rosuvastatin in January of 2018, DSP is actively expanding its statins drug product portfolio, realizing its aspiration of becoming a full-service generics pharmaceutical company. What sets DSP a

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum